农业百科

Zoom in: Venture capital accounted for £2.05 billion of the total, according to the BioIndustry Association’s latest quarterly financing report.

Data from a new study suggest that a form of hyperhidrosis, or excessive sweating, may be due to genetic mutations that result in the overstimulation of the nerves that control the sweat glands. These findings, which are reported in Science Advances , could open a door to targeted treatments for the condition using existing medicines. Full details of the findings are provided in the paper titled “ A neurocutaneous NaV1.8 channelopathy underlies a genetic subtype of primary idiopathic hyperhidrosis .” The international study is led by scientists at Vrije Universiteit Brussel.

Farmers, extension workers and governments now have a powerful new tool to help identify the crops best suited to specific parcels of land, enabling more efficient use of resources and greater resilience to climate change.

[Disclosure: AgFunderNews’ parent company AgFunder is an investor in Sylvarum] Using non-thermal plasma or high voltage …

July 2026, Rome: Under the theme “From Burden Estimates to Solutions: Towards Safe Food Everywhere”, and on the occasion…

A vaccine to prevent pancreatic cancer, targeting common KRAS mutations, was found to be safe and stimulated KRAS-specific T-cell responses in 90% of study participants who were at high risk of developing pancreatic ductal adenocarcinoma (PDAC), according to Phase I clinical trial results. After a median follow-up of 16.5 months, none of the participants developed pancreatic cancer, and some of the precancerous lesions shrank or stopped growing. The study represents the first proof of concept for the use of vaccines for interception of pancreatic cancer in human patients.

Why it matters: The agreements give Orakl a potentially important pharmaceutical validation project for O-Predict, its system for forecasting clinical response and helping drug developers choose patient groups, combinations and trial strategies.

Why it matters: The divestment gives Cambridge-based Mission non-dilutive funding for MTX325, its remaining clinical-stage USP30 inhibitor, while handing the kidney programme to a company already running a global Phase 3 renal trial.

July 2026, Rome : To mark World Food Safety Day 2026, the Iran National Standards Organization (INSO) organized a nation…